Менопаузальная гормональная терапия и сердечно-сосудистая профилактика: желаемое или действительное?
https://doi.org/10.15829/1728-8800-2019-3-94-106
Аннотация
Сердечно-сосудистые заболевания являются основной причиной смерти женщин старших возрастных групп. В течение многих десятилетий проводятся попытки профилактики их развития путем применения эстрогенов. В обзоре литературы представлены современные данные о влиянии менопаузальной гормональной терапии (МГТ) на риск развития сердечно-сосудистых осложнений. Обсуждены результаты основных рандомизированных клинических и обсервационных исследований в этой области, проведенных за несколько десятилетий. Описана концепция «окна возможностей», в соответствии с которой улучшение сердечно-сосудистого прогноза можно ожидать только при начале МГТ у женщин в возрасте до 60 лет в ранней постменопаузе с давностью менопаузы <10 лет. Имеются экспериментальные и клинические данные, объясняющие различное влияние эстрогенов на сердечно-сосудистый прогноз у женщин разных возрастных групп, с разной продолжительностью постменопаузы. Приведенные в обзоре рекомендации по применению МГТ базируются на современных международных руководствах по этому вопросу.
Об авторах
В. И. Подзолков
ФГАОУ ВО Первый Московский государственный медицинский университет им.И.М.Сеченова (Семеновский Университет) Минздрава России
Россия
Россия
Подзолков Валерий Иванович — доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии № 2
Москва
А. Е. Брагина
ФГАОУ ВО Первый Московский государственный медицинский университет им.И.М.Сеченова (Семеновский Университет) Минздрава России
Россия
Россия
Брагина Анна Евгеньевна — доктор медицинских наук, профессор кафедры факультетской терапии №2, профессор
Москва
Н. М. Подзолкова
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия
Россия
Подзолкова Наталия Михайловна — доктор медицинских наук, профессор, заведующая кафедрой акушерства и гинекологии
Москва
Список литературы
1. Mosca L, Hammond G, Mochari-Greenberger H, et al. American Heart Association Cardiovascular Disease and Stroke in Women and Special Populations Committee of the Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on High Blood. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey. Circulation. 2013;127(11):1254-63, e1-29. doi:10.1161/CIR.0b013e318287cf2f.
2. Чазова И. Е., Сметник В. П., Балан В. Е. и др. Ведение женщин с сердечно-сосудистым риском в перии постменопаузе: консенсус российских кардиологов и гинекологов. Consilium Medicum. 2008;10(6):5-18.
3. Wexler DJ, Grant RW, Meigs JB, et al. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. DiabetesCare. 2005;28(3):514-20.
4. Bugiardini R, Yan AT, Yan RT, et al. Canadian Acute Coronary Syndrome Registry I and II Investigators. Factors influencing underutilization of evidence-based therapies in women. Eur Heart J. 2011;32(11):1337-44. doi:10.1093/eurheartj/ehr027.
5. Healy B. The Yentl syndrome. N Engl J Med. 1991;325(4):274-6.
6. Ehrenthal DB, Catov JM. Importance of Engaging Obstetrician/Gynecologists in Cardiovascular Disease Prevention. Curr Opin Cardiol. 2013;28(5):547-53. doi:10.1097/HCO.0b013e328364298e.
7. Mosca L, Greenberger MH, Dolor RJ, et al. Twelve-year follow-up of American Women’s Awareness of cardiovascular disease risk and barriers to heart health. Circulation Cardiovascular quality and outcomes. 2010;3(2):120-7. doi:10.1161/CIRCOUTCOMES.109.915538.
8. Berry TR, Stearns JA, Courneya KS, et al. Women’s perceptions of heart disease and breast cancer and the association with media representations of the diseases J Public Health (Oxf). 2016;38(4):e496-503. doi:10.1093/pubmed/fdv177.
9. Wiviott SD, Cannon CP, Morrow DA, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrestat and determine Cost of Therapy with an Invasive or Conservative Stategy — Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004;109:580-6.
10. Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. Can Med Assoc J. 2007;176(6):S1-44.
11. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: recommendation statement. Ann Intern Med. 2009;150(6):396-404. doi:10.7326/0003-4819-150-6-200903170-00008.
12. Cooke CE, Hammerash WJ Jr. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization. Clin Ther. 2006;28(4):5919. doi:10.1097/MD.0000000000005469.
13. Zhang W, Ji F, Yu X, et al. Factors associated with unattained LDL-cholesterol goals in Chinese patients with acute coronary syndrome one year after percutaneous coronary intervention. Medicine (Baltimore). 2017;96(1):e5469. doi:10.1097/MD.0000000000005469.
14. Dallongevillle J, De Bacquer D, Heidrich J, et al. EUROASPIRE Study Group. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart. 2010;96(21):1744-9. doi:10.1136/hrt.2010.196170.
15. Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. SPRINT Research Group. N Engl J Med. 2015;373(22):2103-16. doi:10.1056/NEJMoa1511939.
16. Kannel W, Hjortland M, McNamara P, et al. Menopause and coronary heart disease. Ann Intern Med. 1976;85:447-52.
17. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-93. doi:10.1161/CIRCULATIONAHA.107.181546.
18. Harlow SD, Gass M, Hall JE, et al. Executive summary of STRAW+10: Addressing the Unfinished Agenda of Staging Reproductive Aging. Climacteric. 2012;15(2):105-14. doi:10.3109/13697137.2011.650656.
19. Lobo RA, Davis SR, de Villiers TJ, et al. Prevention of diseases after menopause. Climacteric. 2014;17:540-56. doi:10.3109/13697137.2014.933411.
20. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
21. Grodstein F, Stampfer MJ, Colditz GA. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-75.
22. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279:688-95.
23. Ross RK, Pike MC, Henderson BE, et al. Stroke prevention and oestrogen replacement therapy. Lancet. 1989;1:505.
24. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-8.
25. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med. 1985;313:1038-43.
26. Woodruff, JD, Pickar JH. The Menopause Study Group. Am J Obstet Gynecol. 1994;170:1213-23.
27. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-13.
28. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-9.
29. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischemic heart disease: the Papworth HRT atherosclerosis study. BJOG. 2002;109:1056-62.
30. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.
31. Herrington DM, Howard TD. From presumed benefit to potential harm — hormone therapy and heart disease. N Engl J Med. 2003;349:519-21. doi:10.1056/NEJMp038108.
32. Goldman JA. The Women’s Health Initiative 2004 — Review and Critique. Med Gen Med. 2004;6(3):65.
33. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative. Hypertension. 2000;36:780-9.
34. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. Women’s Health Initiative Investigators. N Engl J Med. 2003;349(6):523-34. doi:10.1056/NEJMoa030808.
35. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med. 2006;166:357-65. doi:10.1001/archinte.166.3.357.
36. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and cardiovascular disease by age and years since menopause. JAMA. 2007;297:146577. doi:10.1001/jama.297.13.1465.
37. Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. FertilSteril. 2005;83:558-66. doi:10.1016/j.fertnstert.2004.11.012.
38. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women’s Health Initiative clinical trial. Am J Epidemiol. 2005;162:404-14. doi:10.1093/aje/kwi223.
39. L’Hermite M. HRT optimization, using transdermal estradiol plus micronize progesterone, a safer HRT. Climacteric. 2013;16(Suppl.1):44-53. doi:10.3109/13697137.2013.808563.
40. Hodis HN, Collins P, Mock WJ, et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012;12:217-28. doi:10.3109/13697137.2012.656401.
41. Register TC, Appt SE, Clarkson TB. Atherosclerosis and vascular biologic responses to estrogens: histologic, immunohistochemical, biochemical, and molecular methods. Methods Mol Biol. 2016;1366:517-32. doi:10.1007/978-1-4939-3127-9_40.
42. Shively CA, Register TC, Appt SE, Clarkson TB. Effects of long-term sertraline treatment and depression on coronary artery atherosclerosis in premenopausal female primates. Psychosom Med. 2015;77(3):267-78. doi:10.1097/PSY.0000000000000163.
43. Wise PM, Suzuki S, Brown CM. Estradiol: a hormone with diverse and contradictory neuroprotective actions. Dialogues Clin Neurosci. 2009;11(3):297-303.
44. Salpeter SR, Walsh JM, Greyber E, et al. A Brief report. Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J GenIntern Med. 2006;21:363-6. doi:10.1111/j.15251497.2006.00389.x.
45. Salpeter SR, Cheng J, Thabarne L, et al. Bayesian meta-analysis of hormone therapy and mortality in younger women. AnnIntern Med. 2009;122:1016-22. doi:10.1016/j.amjmed.2009.05.021.
46. Salpeter SR, Buckley NS, Liu H, et al. Cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med. 2009;122:42-52. doi:10.1016/j.amjmed.2008.07.026.
47. Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women. A meta-analysis. J Gen Intern Med. 2004;19:791-804. doi:10.1111/j.1525-1497.2004.30281.x.
48. Boardman HM, Hartley L, Eisinga A, et al. Hormonal therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229. doi:10.1002/14651858.CD002229.pub4.
49. Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-case mortality. Menopause. 2015;22:976-83. doi:10.1097/GME.0000000000000450.
50. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ. 2012;345:e6409. doi:10.1136/bmj.e6409.
51. Hodis HN, Mack WJ, Henderson VW. Effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374:1221-31. doi:10.1056/NEJMoa1505241.
52. Юренева С. В., Аверкова В. Г. Вазомоторные симптомы в менопаузе: центральные триггеры, эффекторы и новые возможности патогенетической терапии. Российский вестник акушера-гинеколога. 2018;18(5):43-8. doi:10.17116/rosakush20181805143.
53. Santen RJ. Use of cardiovascular age for assessing risks and benefits of menopausal hormone therapy. Menopause. 2017;24:589-95. doi:10.1097/GME.0000000000000847.
54. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583-7. doi:10.1126/science.1112062.
55. Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017;13(4):220-31. doi:10.1038/nrendo.2016.164.
56. Паневина А. С., Сметнева Н. С., Василенко А. М., Шестакова М. В. Влияние менопаузальной гормональной терапии на содержание провоспалительных цитокинов и иммуноглобулинов при коморбидности сахарного диабета 2-го типа и хронической обструктивной болезни легких в период перименопаузы. Терапевтический архив. 2018;10:79-83. doi:10.26442/terarkh2018901079-83.
57. Gambacciani M, Ciaponi M, Cappagli B, et al. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas. 2001;39:125-32. doi:10.1016/S03785122(01)00194-3.
58. Slopiena R, Wender-Ozegowska E, Rogowicz-Frontczak A, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6-10. doi:10.1016/j.maturitas.2018.08.009.
59. Weber MT, Макі РМ, McDermott MP. Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Мої Biol. 2014;142:90-8. doi:10.1016/j.jsbmb.2013.06.001.
60. Carrasquilla GD, Frumento P, Berglund A, et al. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies. PLoS Med. 2017;14(11):e1002445. doi:10.1371/journal.pmed.1002445.
61. Menopause. Full guideline Clinical Guideline Methods, evidence and recommendations. Version 1.5. NCC-WCH. 2015. https://www.nice.org.uk/guidance/ng23/evidence/full-guideline-559549261 (24 Apr 2019).
62. Baber RJ, Panay N, Fenton A, the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:10950. doi:10.3109/13697137.2015.1129166.
63. Lobo RA, Pickar JH, Stevenson JC, et al. Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis. 2016;254: 282-90. doi:10.1016/j.atherosclerosis.2016.10.005.
64. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 2006;166:1027-32. doi:10.1001/archinte.166.9.1027.
65. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295:1647-57. doi:10.1001/jama.295.14.1647.
66. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161:249-60. doi:10.7326/M14-0353.
67. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res. 1999;43:985-91.
68. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103-11. doi:10.1007/s10549-007-9604-x.
69. Santen RJ, Yue W, Heitjan DF. Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev. 2012;21:1038-48. doi:10.1158/10559965.EPI-12-0043.
70. Tuomikoski P, Lyytinen HJ, Korhonen P. Coronary heart disease mortality and hormone therapy before and after the Women’s Health Initiative. Obstet Gynecol. 2014;124:947-53. doi:10.1097/AOG.0000000000000461.
71. Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009;12:445-53. doi:10.1080/13697130902780853.
72. Сметник В. П., Сухих Г. Т., Андреева Е. Н. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте (клинические рекомендации Минздрава России), 2014. https://minzdrav.gov-murman.ru/activities/akusherstvo/poryadki/menopauza.pdf (24 Apr 2019).
73. Canonico M, Oger E, Plu-Bureau G, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-5. doi:10.1161/CIRCULATIONAHA.106.642280.
74. Smith NL, Blondon M, Wiggins KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med. 2014;174(1):25-31. doi:10.1001/jamainternmed.2013.11074.
75. Blondon M, van Hylckama Vlieg A, Wiggins KL, et al. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers. J Thromb Haemost. 2014;12(6):879-86. doi:10.1111/jth.12560.
76. Vinogradova Y, CouplandC, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the Q Research and CPRD databases. BMJ. 2019;364:k4810. doi:10.1136/bmj.k4810.
77. Cushman M, Kuller LH, Prentice R, et al. Women’s Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573-80. doi:10.1001/jama.292.13.1573.
78. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166:772-80. doi:10.1001/archinte.166.7.772.
79. Hodis HN, Mack WJ, Azen SP, et al. Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349(6):535-45. doi:10.1056/NEJMoa030830.
80. Tsai WC, Haung YB, Kuo HF, et al. Hormone replacement therapy and risk of atrial fibrillation in Taiwanese menopause women: A nationwide cohort study. Sci Rep. 2016;6:24132. 2016 Apr 7. doi:10.1038/srep24132.
81. Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost. 2006;4(6):1259-65. doi:10.1111/j.1538-7836.2006.01933.x.
82. Wingrove CS, Garr E, Godsland IF, et al. 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta. 1998;1406:169-74.
83. Schindler A. E. Differential effects of progestins: European Progestin Club. Maturitas. 2003;46(1):3-5. doi:10.1016/j.maturitas.2003.09.013.
84. Подзолкова Н. М., Кузнецова И. В., Коренная В. В. Гормональная терапия в перии постменопаузе. M.: ГЭОТАР-Медиа. 2012; p.112. ISBN: 978-5-9704-2155-0.
85. Stanczyk FZ, Hapgood JP, Winer S, et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34:171-208. doi:10.1210/er.2012-1008.
86. Honisett SY, Pang B, Stojanovska L, et al. Progesterone does not influence vascular function in postmenopausal women. J Hypertens. 2003;21:1145-9.
87. Boschitsch E, Mayerhofer S, Magometschnigg D. Hypertension in women: the role of progesterone and aldosterone. Climacteric. 2010;13:307-13. doi:10.3109/13697131003624649.
88. Dinger J, Bardenheuer K, Heinemann К. Drospirenone plus estradiol and the risk of setious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349-56. doi:10.1080/13697137.2016.1183624.
89. Hanggi W, Lippuner K, Riesen W, et al. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol. 1997;104:708-17.
90. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001;76(1):13-24. doi:10.1016/S0015-0282(01)01829-5.
91. Sturdee W, Pines A, Archer DF, et al. International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011;14:302-20. doi:10.3109/13697137.2011.570590.
92. de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised Global Consensus Statement on Menopausal Hormone Therapy. Climacteric. 2016;19(4):313-5. doi:10.1080/13697137.2016.1196047.
Рецензия
Для цитирования:
Подзолков В.И., Брагина А.Е., Подзолкова Н.М. Менопаузальная гормональная терапия и сердечно-сосудистая профилактика: желаемое или действительное? Кардиоваскулярная терапия и профилактика. 2019;18(3):94-106. https://doi.org/10.15829/1728-8800-2019-3-94-106
For citation:
Podzolkov V.I., Bragina A.E., Podzolkovа N.M. Menopausal hormone therapy and heart disease prevention: desired or valid? Cardiovascular Therapy and Prevention. 2019;18(3):94-106. (In Russ.) https://doi.org/10.15829/1728-8800-2019-3-94-106
Просмотров:
1682
Послать статью по эл. почте 
